Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTE-X19 in Pediatric and Adolescent Relapsed/Refractory ALL or NHL
NCT02625480Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Feb 2016
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 11
01
Overview
A Phase 2 trial of brexucabtagene autoleucel in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), sponsored by Kite Pharma. Started Feb 2016; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02625480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625480.